Department of Environmental Health Sciences, School of Public Health, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Neurobiol Aging. 2011 Jun;32(6):1079-89. doi: 10.1016/j.neurobiolaging.2009.06.003. Epub 2009 Jul 14.
Accumulation of amyloid beta peptide (Aβ) in the brain is a pathological hallmark of Alzheimer's disease (AD); the underlying mechanism, however, is not well understood. In this study, we show that expression of plasminogen activator inhibitor 1 (PAI-1), a physiological inhibitor of tissue type and urokinase type plasminogen activators (tPA and uPA), increases with age in the brain of wild type and Aβ precursor protein-presenilin 1 (APP/PS1) transgenic mice as well as in AD patients. Most importantly, we show that knocking out the PAI-1 gene dramatically reduces Aβ burden in the brain of APP/PS1 mice but has no effect on the levels of full-length APP, alpha or beta C-terminal fragments. Furthermore, we show that knocking out the PAI-1 gene leads to increases in the activities of tPA and plasmin, and the plasmin activity inversely correlates with the amounts of SDS insoluble Aβ40 and Aβ42. Together, these data suggest that increased PAI-1 expression/activity contributes importantly to Aβ accumulation during aging and in AD probably by inhibiting plasminogen activation and thus Aβ degradation.
淀粉样β肽(Aβ)在大脑中的积累是阿尔茨海默病(AD)的病理标志;然而,其潜在机制尚不清楚。在这项研究中,我们表明,纤溶酶原激活物抑制剂 1(PAI-1)的表达,一种组织型和尿激酶型纤溶酶原激活物(tPA 和 uPA)的生理抑制剂,在野生型和 Aβ前体蛋白-早老素 1(APP/PS1)转基因小鼠以及 AD 患者的大脑中随年龄增长而增加。最重要的是,我们表明,敲除 PAI-1 基因可显著降低 APP/PS1 小鼠大脑中的 Aβ负担,但对全长 APP、α或β C 端片段的水平没有影响。此外,我们表明,敲除 PAI-1 基因可导致 tPA 和纤溶酶的活性增加,而纤溶酶的活性与 SDS 不溶性 Aβ40 和 Aβ42 的量呈负相关。总之,这些数据表明,PAI-1 表达/活性的增加在衰老和 AD 期间对 Aβ的积累有重要贡献,可能是通过抑制纤溶酶原的激活,从而抑制 Aβ的降解。